u/soulpost

For the past decade, limiting children's screen time has been one of parenting's most confident positions. The American Academy of Pediatrics has issued guidelines. Schools have banned phones. Parents have negotiated, bargained, and enforced limits. The underlying assumption has been consistent: screens displace the activities that build children's brains, and more time on them means worse cognitive outcomes.

A research team at the Universities of Jyväskylä and Eastern Finland decided to test that assumption longitudinally. They enrolled children at around age 7 and followed them for eight years, measuring their physical activity, sedentary behavior, and screen time at regular intervals. At the end of the follow-up, when participants were around 15 years old, they sat the children down and tested their cognitive performance using a validated battery measuring learning, attention, and working memory.

The children who had accumulated more screen time over those eight years did not score worse. They scored better.

The researchers say the finding does not mean unlimited screen time is harmless. But it does challenge the assumption that screen time and brain development are simply in opposition, and it raises a question that the decade of warning labels, app timers, and parental anxiety largely skipped over: what are children actually doing on those screens?

The conversation around male domestic violence has centered on a consistent explanation for why men do not seek help. Shame. Stigma. The fear of not being believed. The expectation that men should handle problems on their own. These have been the assumed barriers for decades, and they have shaped how support services are designed, how awareness campaigns are framed, and how researchers have studied the problem.

A new study from George Mason University recruited 1,200 men who had experienced intimate partner violence perpetrated by a female partner, across Black, Latino, and White communities, and asked them directly: what stopped you from seeking help?

The researchers were specifically trying to understand whether the barriers differed across racial and ethnic groups, which previous research had rarely examined in depth. What they found instead was something more fundamental. Across all three groups, the most commonly cited barrier was the same.

It had nothing to do with shame, stigma, or fear of being disbelieved. Men said they simply viewed what was happening to them as a private matter. Not something to be reported. Not something that crossed a threshold where outside help was warranted. Just private.

That finding changes the question entirely. If the primary barrier is not shame but a cognitive categorization of abuse as inherently personal, then campaigns built around reducing stigma may be missing the most important thing stopping men from getting help.

When you got vaccinated against COVID, or when you recovered from infection, your immune system did something it always does after a fight. It kept a record. A population of T cells, trained specifically to recognize the SARS-CoV-2 spike protein, took up residence in your body and has been waiting there ever since. For most people, those cells will never be called upon again. They are a standing army with no remaining enemy.

Researchers at Case Western Reserve University, University Hospitals, and the biotech company Celloram looked at that biological fact and asked a question nobody had thought to ask before: what if you could give that army a new target?

The challenge they were trying to solve is one of the oldest problems in cancer immunotherapy. Tumors are not foreign invaders. They are the body's own cells gone wrong, which makes them nearly invisible to the immune system. Training the immune system to attack cancer from scratch requires identifying tumor-specific signals, building a new immune response around them, and somehow getting that response to generate enough force to overwhelm a growing tumor. It is slow, expensive, and often fails.

PROTEXI does not build from scratch. It borrows.

The platform works by linking tumor-specific antigens to fragments of the COVID spike protein that T cells already recognize. When the vaccine is administered, the immune system sees the COVID fragment and activates its existing memory response. That response is then redirected toward the tumor antigen attached to it, converting a dormant antiviral memory into an active antitumor attack.

In mouse models of breast cancer and melanoma, tumors that had been evading the immune system entirely became visible. Tumor growth slowed. Survival improved. The immune system built a new memory against the cancer itself, one that persisted after the initial response ended.

Human trials have not begun yet. But the biological logic of what this platform is attempting may be unlike anything cancer immunotherapy has tried before.

For the past decade, the loneliness epidemic has been one of public health's most discussed crises. The US Surgeon General issued an advisory about it. Countries have appointed ministers for loneliness. Research articles have cited loneliness as a risk factor for dementia, heart disease, and early death. The assumption behind all of it is intuitive: feeling alone is what hurts you.

A study just published in the Journal of Gerontology has tested that assumption directly, using 14 years of data from 30,421 older Americans and a statistical technique that simulates what happens when you change one variable while holding everything else constant.

The researchers separated two things that almost everyone treats as interchangeable. Social isolation is objective: do you live alone, have a partner, see family or friends, participate in groups? Loneliness is subjective: do you feel disconnected, regardless of your actual circumstances?

Then they ran the causal models and measured which one was actually damaging the brain.

Loneliness accounted for 6% of the cognitive protection when social connection improved. The other 94% had nothing to do with how people felt at all.

If you have Crohn's disease or ulcerative colitis, you have probably been told that the depression and anxiety so common in IBD patients come from the burden of living with a chronic illness. The diagnosis is difficult, the symptoms are disruptive, the treatments are demanding. Of course the mental health suffers. The timing seems obvious.

A new study just showed the timing is wrong.

Researchers in Sweden tracked 43,862 IBD patients from 2007 through 2023, comparing them against nearly 180,000 matched controls from the general population and, crucially, against 26,000 of their own IBD-free full siblings. That sibling comparison is what makes this study different from everything before it: siblings share roughly half their genetics and grew up in the same household, so any difference in psychiatric risk between them cannot be explained by family history or upbringing.

The psychiatric risk in IBD patients started rising two to three years before any gut diagnosis was made. By the time patients received their formal IBD diagnosis, the risk of developing a psychiatric disorder had already been climbing for years. It peaked at 50% higher than controls within the first six months after diagnosis, then gradually declined but remained elevated a full decade later.

The finding forces a different question. If the mental health crisis starts before the gut disease is even identified, what exactly is driving it?

The standard medical explanation for male sexual desire has always been testosterone. Testosterone is highest in the late teens and early 20s, it declines gradually with age, and so, the logic went, desire follows the same trajectory. It is one of those assumptions so widely repeated that questioning it barely seems necessary.

A team at the University of Tartu in Estonia decided to question it anyway. They had access to the Estonian Biobank, a population-level repository containing biological samples and lifestyle data from a substantial share of the country's adult population. They pulled data from 67,334 adults aged 18 to 89 and asked them to rate their general level of sexual desire. Then they matched those answers against age, gender, relationship status, sexual orientation, parenthood, and a range of other factors.

Men's desire did not peak in youth. It rose steadily through early adulthood, reached its highest point in the late 30s and early 40s, and then declined gradually rather than sharply.

Even more unexpected: men in their 60s reported levels of desire comparable to men in their 20s. The testosterone explanation does not account for any of this. The researchers say something else entirely is shaping the trajectory.

For the past several years, millions of pregnant women have faced a genuinely frightening question: does taking Tylenol during pregnancy increase the risk of autism or ADHD in their child?

The concern was not invented by the internet. Multiple peer-reviewed studies reported a real association. The FDA proposed label changes. In September 2025, President Trump publicly linked acetaminophen use in pregnancy to autism, sending anxiety levels even higher among expecting parents. Doctors were caught between reassuring patients and acknowledging the mixed research.

A team at the University of Hong Kong just published a study in JAMA Internal Medicine that may finally settle the debate. Their approach was different from everything that came before it. Instead of comparing children of mothers who took Tylenol to children of mothers who did not, they compared siblings from the same family, children whose mother took acetaminophen during one pregnancy but not another.

The logic is precise: siblings share roughly half their genetics and grow up in the same household. If the drug causes autism, the exposed sibling should show higher rates. If the association disappears when you compare within the same family, the earlier findings were picking up something else entirely.

They did this across 708,020 children. The result was 1.00 for autism and 1.01 for ADHD. Exactly no difference.

Millions of people with long COVID report the same cluster of symptoms: a crushing lack of motivation, an inability to think clearly, memory that slips, movements that feel slower than they should. For years, these complaints sat in an uncomfortable medical grey zone. The symptoms were real, the patients were suffering, but the biological explanation remained frustratingly out of reach.

A team at the University of Toronto just published what may be the clearest physical evidence yet for what is actually happening in these patients' brains. They brought 24 long COVID sufferers into a lab and used positron emission tomography, the same imaging technology used to diagnose Parkinson's disease, to directly measure the health of the dopamine system deep inside the brain.

Most of the research on LSD focuses on the experience itself: what people see, feel, and think while the drug is active. The hours during the trip are treated as the event. What comes after is treated as the aftermath, a return to normal.

A new study from the University of Fribourg asked a different question. Instead of measuring what LSD does while people are on it, researchers waited. They gave 45 healthy adults a full clinical dose and sent them home. They did not test them that day.

One week later, participants came back. The researchers measured their stress levels using validated psychological scales. They measured their ability to generate alternative solutions to difficult problems, a core component of cognitive flexibility. They ran motor learning tests. They took brain measurements.

What they found in that one-week window was not what most people would expect from a drug that had finished working six days earlier.

Researchers at UTHealth Houston tracked 1,066 young people from the age of 12 through seven annual surveys, following them from 2018 all the way to 2025. By the final wave, the average participant was nearly 20. They had grown up alongside TikTok. They were the first cohort to go through adolescence with short-form video as a constant backdrop. And when the researchers measured their mental health against how much time they spent on social media each day, the results followed a dose-response curve that held firm even after controlling for sex, race, ethnicity, and income.

Young adults who spent six or more hours daily on social media were 2.63 times more likely to show symptoms of anxiety than those who used it less than an hour a day. Their odds of reporting suicidal ideation in the past year were 3.23 times higher.

The relationship wasn’t a cliff edge — it was a slope. Anxiety and depression both climbed steadily as daily usage increased, from under one hour all the way through the six-hour threshold. Every level of additional use was associated with additional risk.

Tens of millions of people are taking Ozempic, Wegovy, and Mounjaro right now. Most know about the nausea. Many have heard the rarer concerns. But one complaint has been building in patient forums and doctor's offices for two years, documented in FDA reports but never rigorously quantified.

Researchers at the University of Pennsylvania just published the largest study to examine it directly. Nearly 40,000 patients. Compared not to the general population, but to people taking other diabetes medications — the most rigorous way to isolate a drug effect.

People on GLP-1 drugs were 37% more likely to develop hair loss than those on one comparison drug class, and 68% more likely than those on another.

The absolute risk remains low. But the FDA has already said it is evaluating the signal. And the timing of when the hair loss tends to appear, clustering just before the one-year mark, tells its own story about what might be driving it.

Roughly one in five people identify as highly sensitive. They notice more. They feel more. Sounds are louder, lights are brighter, smells hit harder. The standard description of the highly sensitive person, repeated in dozens of books and across thousands of online communities, is built on the assumption that something about their senses is fundamentally more acute.

A team at the University of Bern just put that assumption to a direct test. 150 people. Objective laboratory measurements across hearing, vision, smell, temperature, and balance. Detection thresholds and pain thresholds both measured and compared.

Highly sensitive people detected sounds at the same minimum volumes as everyone else. Lights at the same minimum intensities. Temperature changes at the same minimum levels. Not slightly less sensitive. Not slightly more. The same.

But here is the part that matters: they still reported feeling more sensitive. They still experienced stimulation as more overwhelming. The experience is real. The mechanism behind it is not what most people think it is.

Everyone knows that Alzheimer's destroys memory. What gets far less attention is what it does to sleep.

Patients with Alzheimer's lose hours of restorative sleep every night, for years. The assumption has always been that the same amyloid plaques destroying neurons were also disrupting sleep.

Researchers at the University of Kentucky just showed that assumption was wrong. They silenced 87% of the brain's immune cells in mice with Alzheimer's pathology, leaving every single plaque completely untouched. More than two hours of restorative sleep came back.

The immune cells, called microglia, had been responding to the plaques by triggering an inflammatory cascade that essentially kept the brain awake all night. Not the plaques. The immune response to them.

And here is what made the finding even stranger: when they compared mice with early-stage disease to mice with twice as many plaques, the sleep loss was exactly the same. The damage was done by the first immune storm and stayed there, regardless of how many more plaques accumulated afterward.

More than 90 percent of cancer deaths are not caused by the original tumor. They are caused by metastasis — the process through which cancer cells travel through the bloodstream and establish new colonies in distant organs.

Scientists have long known that cancer cells somehow become better at spreading as they spread. What they didn't know was why.

A new study from the Chinese Academy of Sciences has found the answer, and it changes how we think about what happens inside the body when cancer travels.

When cancer cells are physically squeezed through the narrow capillaries they must navigate to reach distant organs, that compression itself activates a molecular program that makes the cells structurally stronger and better at squeezing through the next tight space.

The tumor isn't just finding cells capable of spreading. The act of spreading is training them in real time.

The researchers identified the exact enzyme at the center of this process. Blocking it dramatically reduced metastasis in animal models. And the same enzyme was elevated in human cancer patients whose tumors had already spread.

When two people click, something changes between them. Conversations flow. Silences feel comfortable rather than awkward. Both people later describe the exchange as easy, natural, meaningful. For most of human history this was understood as chemistry, personality, luck. A decade of neuroscience research now suggests it is something more literal: a measurable physical event happening inside two skulls simultaneously, one that can be tracked in real time, predicted before it happens, and deliberately engineered.

A research team led by Suzanne Dikker of New York University and Ghent University has spent ten years strapping portable electroencephalogram headsets onto high school students, museum visitors, festival crowds, and musicians, recording their brainwave patterns during natural face-to-face interaction. The findings, published in Trends in Cognitive Sciences, document what they call social synchrony: the moment-by-moment alignment of brain rhythms between people engaged in genuine communication. When synchrony is high, people report liking each other more, learning better, and feeling less alone. When it is absent, the neural signature is distinctive. And the researchers have now found they can tip the balance deliberately.

Fifteen people took the same dose of psilocybin. Half of them took it inside an MRI scanner. The other half took it in a comfortable room with music, artwork, and a supportive guide.

A week later, scientists scanned everyone's brains using imaging sensitive enough to measure synaptic density at the molecular level. The two groups had measurably different brains.

The people who took psilocybin in the therapeutic room showed greater increases in synaptic connections than those who took the same drug in the scanner. They also reported more lasting psychological benefits three months later. Same drug. Same dose. Different room. Different brain.

The field of psychedelic therapy has spent a decade asking how the drug works. This study suggests that may be the wrong question.

For decades, neuroscience taught that the brain makes decisions at the top. Sensory information travels upward through layers of increasing complexity, and somewhere near the frontal cortex, a decision gets made. The sensory regions at the bottom do their job and pass the information along.

Researchers at the University of Illinois recorded what is actually happening in the brain while a decision forms.

The decision does not wait for information to reach the top. It starts at the very first sensory layer, earlier than the model says is possible, driven by signals flowing downward from higher brain regions before the sensory processing is even finished.

The bottom of the hierarchy and the top are talking to each other simultaneously, not in sequence. And that bidirectional conversation appears to be what a decision actually is.

The implications for how AI is built, and why it uses so much more energy than the brain, are significant.